1. Potential biomarker for acute myeloid leukaemia therapy.
- Author
-
Gourd E
- Subjects
- Aminoglycosides adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Tumor immunology, Clinical Trials, Phase III as Topic, Disease-Free Survival, Gemtuzumab, Humans, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute pathology, Randomized Controlled Trials as Topic, Sialic Acid Binding Ig-like Lectin 3 immunology, Treatment Outcome, Aminoglycosides administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Leukemia, Myeloid, Acute drug therapy, Polymorphism, Single Nucleotide, Sialic Acid Binding Ig-like Lectin 3 genetics
- Published
- 2017
- Full Text
- View/download PDF